Barclays’s Acutus Medical Inc AFIB Stock Holding History

Barclays’s Portfolio AFIB Stock Details AFIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3,104	Closed	-$5K	–	5347
2022 Q1	$5K	Buy	+3,104	New	+$6.64K	﹤0.01%	4705

Other funds holding AFIB

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KSCM

Kamunting Street Capital Management Miami Beach, Florida $183M AUM 2.19% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

AFG

American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Barclays's AFIB Position: Q2 2022 in Review

Barclays sold out of Acutus Medical Inc (AFIB) in Q2 2022, closing a stake of 3,104 shares — an estimated $5K sold.

Barclays first reported a position in AFIB in Q1 2022 and held it in 1 quarter. The position peaked at $5K in Q1 2022. 47 funds tracked by Wall St. Rank hold AFIB as of Q2 2022.

Barclays reported no remaining Acutus Medical Inc position as of Q2 2022 after selling out during the quarter.
Barclays sold 3,104 Acutus Medical Inc shares in Q2 2022, an estimated $5K.
Barclays first reported a position in Acutus Medical Inc in Q1 2022 and held it in 1 quarter.
Barclays's Acutus Medical Inc position peaked at $5K in Q1 2022.
47 funds tracked by Wall St. Rank held Acutus Medical Inc as of Q2 2022.

Based on Barclays's 13F filing for Q2 2022, filed 12 Aug 2022.